Does TOFACITINIB Cause Neoplasm malignant? 1,020 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 1,020 reports of Neoplasm malignant have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.7% of all adverse event reports for TOFACITINIB.
1,020
Reports of Neoplasm malignant with TOFACITINIB
0.7%
of all TOFACITINIB reports
70
Deaths
207
Hospitalizations
How Dangerous Is Neoplasm malignant From TOFACITINIB?
Of the 1,020 reports, 70 (6.9%) resulted in death, 207 (20.3%) required hospitalization, and 35 (3.4%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 1,020 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
DENOSUMAB (698)
Which TOFACITINIB Alternatives Have Lower Neoplasm malignant Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN